<DOC>
	<DOCNO>NCT02502812</DOCNO>
	<brief_summary>Clopidogrel potent anti-thrombotic drug inhibits adenosine diphosphate ( ADP ) -induced platelet aggregation . This open-label , randomize , single dose , three-way cross , six sequence study investigate relative bioavailability two 75 milligram ( mg ) clopidogrel tablet formulation ( clopidogrel SB224326 test formulation 1 [ Clop F1 ] clopidogrel SB224326 test formulation 2 [ Clop F2 ] ) compare reference product ( innovator ) healthy human subject . A total 18 healthy human subject randomize , approximately 14 evaluable subject complete study . Total duration study subject approximately 8 week screen follow-up visit .</brief_summary>
	<brief_title>Bioequivalence Study Clopidogrel 75 mg Two Tablet Formulations Relative Reference Tablet Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Adult subject age 18 65 year age inclusive , time signing informed consent . Healthy , nonsmoker , determine investigator medically qualify designee base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include investigator consultation Medical Monitor require , agree document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; =50 kilogram ( kg ) Body mass index ( BMI ) within range 19 24.9 kg/square meter ( m^2 ) ( inclusive ) . Healthy male female subject : MALES : Male subject female partner child bear potential must comply follow contraception requirement time first dose study medication 24 hour last dose study medication : ) Vasectomy documentation azoospermia . b ) Male condom plus partner use one contraceptive follow option : Contraceptive subdermal implant , Intrauterine device intrauterine system , Oral Contraceptive , either combined progestogen alone , Injectable progestogen , Contraceptive vaginal ring , Percutaneous contraceptive patch , This inclusive list method meet GlaxoSmithKline ( GSK ) definition highly effective : failure rate le 1 % per year use consistently , correctly , applicable , accordance product label . For nonproduct method ( e.g . male sterility ) , investigator determines consistent correct use . The GSK definition base definition provide International Conference Harmonisation Technical Requirements Registration Pharmaceuticals Human Use ( ICH ) . The investigator responsible ensure subject understand properly use method contraception . FEMALES : Eligible participate , pregnant ( confirmed negative serum human chorionic gonadotrophin [ hCG ] test ) , lactate , least one follow condition applies : ) Nonreproductive potential define : Premenopausal females one following : Documented tubal ligation , Documented hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion , Hysterectomy , Documented Bilateral Oophorectomy , Postmenopausal define 12 month spontaneous amenorrhea ( questionable case blood sample simultaneous follicle stimulate hormone [ FSH ] estradiol level consistent menopause ) . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one highly effective contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment . b ) Reproductive potential agrees follow one option list Modified List Highly Effective Methods Avoiding Pregnancy Females Reproductive Potential ( FRP ) 30 day prior first dose study medication 24 hour last dose study medication completion followup visit . Capable give write informed consent , include compliance requirement restriction list consent form . Innovator product contains lactose subject lactose intolerance include . Alanine aminotransferase ( ALT ) bilirubin &gt; 1.5xupper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) Corrected QT interval ( QTc ) &gt; 450 millisecond ( msec ) NOTES : The QTc QT interval correct heart rate accord Bazett 's formula ( QTcB ) , Fridericia 's formula ( QTcF ) , and/or another method , machineread manually overread . The specific formula use determine eligibility discontinuation individual subject determine prior initiation study . In word , several different formula use calculate QTc individual subject low QTc value use include discontinue subject trial . For purpose data analysis , QTcB , QTcF , another QT correction formula , composite available value QTc use . The following medication increase risk bleeding : Nonsteroidal antiinflammatory drug ( NSAIDs ) , warfarin , selective serotonin serotonin norepinephrine reuptake inhibitor ( SSRIs , SNRIs ) . Proton pump inhibitor : drug class inhibitory effect formation clopidogrel active metabolite . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 gram ( g ) alcohol : halfpint ( ~240 milliliter [ mL ] ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . History sensitivity heparin heparininduced thrombocytopenia . History sensitivity study medication , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation . Active pathological bleeding , peptic ulcer intra cranial haemorrhage Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment . A positive prestudy drug/alcohol screen . A positive test Human Immunodeficiency Virus ( HIV ) antibody . Where participation study would result donation blood blood product excess 500 mL within 90 day period . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 90 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Gastrointestinal disease gastrointestinal surgical history affect absorption investigational drug . Any symptom systolic blood pressure ( BP ) &lt; 95 millimeter mercury ( mmHg )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>bioequivalence</keyword>
	<keyword>SB224326</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>Relative bioavailability</keyword>
</DOC>